Caradigm, Eliza partner for more efficient behavior change

Enterprise population health vendor Caradigm is partnering with health engagement management provider Eliza to drive behavior change.

Eliza is a leader in health engagement management and the collaboration will lead to patient relationship management across the care continuum to improve outcomes.

The new Caradigm Patient Outreach solution aims to engage patients in health-related behavior change outside of the care setting. Interactions are targeted based on patients’ clinical and life circumstances, making them more relevant and compelling, leading to improved patient activation, according to a release. The system also continues to gain insights about patients based on each interaction, resulting in improvements in both the effectiveness of interactions and patients’ perceptions of their provider organizations.

Caradigm Patient Outreach is designed to help improve patient safety, ensure clinical best practice delivery and maintain regulatory compliance by establishing rapport with patients, supporting patients through transitions of care and filling gaps in care.

The Patient Outreach solution will be available in the second half of 2015.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.